Limited coverage criteria – tofacitinib for ulcerative colitis
Last updated on July 17, 2025
Return to Special Authority drug list
Tofacitinib coverage transition
PharmaCare is transitioning tofacitinib coverage from the brand name product Xeljanz® to generic tofacitinib products. According to Health Canada, generic drugs are pharmaceutically equivalent to brand name drugs; they contain the identical medicinal ingredients, in the same amounts and in a similar dosage form.
To maintain coverage, patients currently covered for the brand name product Xeljanz must transition to a generic tofacitinib product. PharmaCare is providing six-month transitional coverage ending January 15, 2026, to allow time for patients to switch.For patients with existing Xeljanz Special Authority approval, the generic tofacitinib products will automatically be covered; prescribers do not need to submit a new Special Authority request until the next scheduled renewal date (if applicable).
| July 16, 2025 | July 16, 2025, to January 15, 2026 | January 16, 2026 |
|---|---|---|
| All new Special Authority requests, including renewals, for tofacitinib will only be approved for the generic brand products. The brand product Xeljanz will not be approved for new Special Authority requests, including renewals. | To maintain coverage, patients with existing Xeljanz Special Authority approval must transition to the generic brand of tofacitinib within the six-month transition period. | Xeljanz is no longer a PharmaCare benefit and only the generic tofacitinib products are covered. |
Special Authority requests for patients who are unable to transition to any formulation of generic tofacitinib will be considered on a case-by-case basis. Prescribers can submit HLTH 5861 – Tofacitinib patient list request (PDF, 968KB) form to request a list of their patients who are receiving PharmaCare coverage for Xeljanz so they can contact them to start the switch. PharmaCare will not be offering patient support fees for the transition.
Patient support programs
For patients transitioning to a generic tofacitinib product, a different patient support program is available. PharmaCare coverage is not tied to participation in a patient support program.
| Generic manufacturer | Patient support program (PSP) | |
| Taro (taro-tofacitinib) |
Sun360 |
|
| PharmaScience (PMS-tofacitinib) |
Tel: 1-888-255-9777
|
|
| JAMP (JAMP-tofacitinib) |
JAMP Care |
|
| Auro (Auro-tofacitinib) | Auro generics are available; please follow up with them for their PSP information. Their general contact information is provided below:
Tel: 1-905-856-8063 Ext: 242 |
|
For questions or concerns, please contact the Formulary Management team by email at FM.GenericMailbox@gov.bc.ca.
Generic name |
tofacitinib |
|---|---|
Strength & form |
5 mg, 10 mg tablet |
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of moderate to severe ulcerative colitis (UC), according to criteria detailed in HLTH 5388 (Initial/Switch) (PDF, 657KB) or HLTH 5497 (Renewal) (PDF, 653KB), AND When a Special Authority request is submitted by a gastroenterologist |
Initial: 8 weeks Renewal: 1 year |
Practitioner exemptions
- None
Special notes
- PharmaCare covers a maximum 30 days' supply per fill
- Coverage is limited to 10 mg twice daily dosing for 8 weeks (loading doses) then 5 mg twice daily dosing thereafter
- Cannot be used in combination with biologic drugs for ulcerative colitis